Bukwang Pharmaceutical Signs Export Agreement for Dexid Tab with Pacific Healthcare in Thailand
"Accelerating Overseas Market Expansion"
Bukwang Pharmaceutical announced on August 4 that it has signed an exclusive export contract with Pacific Healthcare for the diabetic polyneuropathy treatment 'Dexid Tab (active ingredient: thioctic acid tromethamine salt)' at Pacific Healthcare's headquarters in Bangkok, Thailand.
Jiyoung Lee, CEO of Bukwang Pharmaceutical (left), and Patrick Brulman, CEO of Pacific Healthcare, are posing for a commemorative photo after signing the Dexid export contract to Thailand. Bukwang Pharmaceutical
View original imageUnder this agreement, Pacific Healthcare will be responsible for obtaining regulatory approval, marketing, and distribution of Dexid Tab in Thailand, while Bukwang Pharmaceutical will supply the product and provide local regulatory support, officially entering the Thai market.
Dexid Tab is an improved drug formulation of alpha-lipoic acid developed by Bukwang Pharmaceutical and launched in 2014. It is a prescription drug used to treat diabetic polyneuropathy and is recommended as a disease-modifying therapy in diabetes treatment guidelines both in Korea and internationally. It is currently sold in Korea, Cambodia, and the Philippines, with the approval process underway in Vietnam.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jaeyoung Lee, CEO of Bukwang Pharmaceutical, said, "With this agreement, we plan to accelerate the expansion into overseas markets."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.